Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer
about
Targeting BCL2-Proteins for the Treatment of Solid TumoursIL-6 regulates Mcl-1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an anti-apoptotic role during liver regenerationProteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cellsCombination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancerA reciprocal role of prostate cancer on stromal DNA damage.Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer.Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.Broad targeting of resistance to apoptosis in cancer.Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis.Cancer subclonal genetic architecture as a key to personalized medicine.Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway.Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice.PTBP1 modulation of MCL1 expression regulates cellular apoptosis induced by antitubulin chemotherapeutics.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationTargeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner.MCL-1 inhibition in cancer treatment
P2860
Q26853686-3843C8CC-0C62-4558-BAC2-3E1AD320EDAAQ28534312-D99D77C8-E5D8-43FE-9C86-6378453081E1Q28534817-1DB12DAD-05F6-4686-8BC7-3FA3462AC116Q30557008-98683338-3C23-4E9E-9DBB-9D960AE58220Q34000472-2E08CDEB-E075-494B-B62F-BFD01C305421Q35078001-00AF240D-0ABC-4398-8721-AA7C4F7D4651Q35794952-E5622F0A-CC94-4872-9891-DB688C914801Q36140893-E790DC2F-7A11-439F-8F34-647227EC2C64Q36483749-AC333828-9266-4066-981C-31A77CCB942AQ36801115-B0BB89A7-D351-4F95-AE84-0188AB259813Q37448116-6871B66C-C0D0-4374-83C3-A2C72671F2B1Q38112122-0C46F6C1-5B59-4A20-884B-D44650DE53B8Q38151753-F3582692-8220-4618-906B-B6CC3CCAEC2DQ38762598-1E8FA45F-6443-40A3-A762-8D114A3AC93DQ41636962-8062C126-7799-4818-932F-FE2DBD7614D5Q41879186-DBA0BC83-E394-489A-B15C-054866FE0357Q51746852-92A5C34D-387F-499E-A36D-87241CAD4CDFQ53677449-41C8ABC5-1C25-41BB-903D-630D1683C67FQ58694408-1473CEC9-A3C3-415C-A46C-EE7DBF679E94
P2860
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Sabutoclax, a Mcl-1 antagonist ...... raft models of prostate cancer
@ast
Sabutoclax, a Mcl-1 antagonist ...... raft models of prostate cancer
@en
type
label
Sabutoclax, a Mcl-1 antagonist ...... raft models of prostate cancer
@ast
Sabutoclax, a Mcl-1 antagonist ...... raft models of prostate cancer
@en
prefLabel
Sabutoclax, a Mcl-1 antagonist ...... raft models of prostate cancer
@ast
Sabutoclax, a Mcl-1 antagonist ...... raft models of prostate cancer
@en
P2093
P2860
P356
P1433
P1476
Sabutoclax, a Mcl-1 antagonist ...... raft models of prostate cancer
@en
P2093
Ana Fernandez
Chia-Yi Chu
Gloria Fritz
John C Reed
John Stebbins
Leland W Chung
Maurizio Pellecchia
Neil A Bhowmick
Roger S Jackson
P2860
P304
P356
10.1593/NEO.12640
P577
2012-07-01T00:00:00Z